HealthCo Healthcare and Wellness REIT (ASX: HCW) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
HealthCo Healthcare and Wellness REIT Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
HealthCo Healthcare and Wellness REIT (ASX: HCW)
Latest News
Dividend Investing
3 ASX dividend shares to supercharge your passive income
Healthcare Shares
A 'golden era' is coming for these ASX healthcare shares
Dividend Investing
Want a 6%+ yield? 3 ASX dividend shares to buy this week
Dividend Investing
These buy-rated ASX dividend shares offer 6% yields
Dividend Investing
Analysts name 4 ASX dividend shares to buy for passive income
Dividend Investing
3 high-yield ASX dividend shares that are great buys right now
Dividend Investing
Buy these ASX dividend stocks with 7%+ yields
Dividend Investing
Should you buy BHP and these ASX dividend shares?
Dividend Investing
3 ASX dividend stocks with 7%+ yields to buy now
Dividend Investing
3 ASX dividend shares to buy with 6%+ yields
Dividend Investing
4 ASX dividend shares to buy next week
Dividend Investing
5 ASX dividend stocks to buy with 6%+ yields
Frequently Asked Questions
-
Yes, HealthCo Healthcare and Wellness REIT has historically paid four unfranked unitholder distributions a year.
-
HealthCo Healthcare and Wellness REIT generally pays its unitholder distributions in February, May, August, and November.
-
HealthCo Healthcare and Wellness REIT listed on the ASX on 6 September 2021.
Dividend Payment History Data provided by Morningstar.
Ex-Date | Amount | Franking | Type | Payable |
---|---|---|---|---|
27 Sep 2024 | $0.0210 | 0.00% | Interim | 22 Nov 2024 |
27 Jun 2024 | $0.0200 | 0.00% | Final | 22 Aug 2024 |
27 Mar 2024 | $0.0200 | 0.00% | Interim | 22 May 2024 |
28 Dec 2023 | $0.0200 | 0.00% | Interim | 21 Feb 2024 |
28 Sep 2023 | $0.0200 | 0.00% | Interim | 29 Nov 2023 |
29 Jun 2023 | $0.0200 | 0.00% | Final | 30 Aug 2023 |
01 May 2023 | $0.0188 | 0.00% | Interim | 23 Jun 2023 |
29 Dec 2022 | $0.0188 | 0.00% | Interim | 24 Feb 2023 |
29 Sep 2022 | $0.0188 | 0.00% | Interim | 25 Nov 2022 |
29 Jun 2022 | $0.0225 | 0.00% | Final | 22 Aug 2022 |
30 Mar 2022 | $0.0225 | 0.00% | Interim | 20 May 2022 |
30 Dec 2021 | $0.0300 | 0.00% | Interim | 25 Feb 2022 |
HCW ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About HealthCo Healthcare and Wellness REIT
HealthCo Healthcare and Wellness REIT (ASX: HCW) owns and manages a portfolio of commercial health and wellness real estate assets. The REIT is under the umbrella of HMC Capital (ASX: HMC), a listed asset manager that invests on behalf of individuals, large institutions, and super funds.
HealthCo Healthcare and Wellness REIT holds a $1.6 billion portfolio of 36 properties including hospitals, aged care, childcare, life sciences and research facilities as well as primary care and wellness assets. The portfolio covers Queensland, New South Wales, Victoria, and Western Australia with a weighted average lease expiry (WALE) of 12 years.
HCW Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
20 Dec 2024 | $1.00 | $0.00 | 0.00% | 3,450,972 | $1.02 | $1.02 | $1.00 |
19 Dec 2024 | $1.01 | $-0.03 | -2.90% | 3,725,549 | $1.02 | $1.02 | $0.99 |
18 Dec 2024 | $1.04 | $0.00 | 0.00% | 2,688,000 | $1.03 | $1.06 | $1.03 |
17 Dec 2024 | $1.03 | $0.02 | 1.97% | 1,710,612 | $1.01 | $1.04 | $1.01 |
16 Dec 2024 | $1.02 | $-0.02 | -1.94% | 2,943,455 | $1.03 | $1.05 | $1.01 |
13 Dec 2024 | $1.03 | $0.00 | 0.00% | 1,234,369 | $1.04 | $1.05 | $1.03 |
12 Dec 2024 | $1.04 | $-0.01 | -0.96% | 1,125,048 | $1.05 | $1.06 | $1.03 |
11 Dec 2024 | $1.05 | $0.00 | 0.00% | 1,485,302 | $1.06 | $1.06 | $1.04 |
10 Dec 2024 | $1.04 | $-0.01 | -0.95% | 2,052,541 | $1.05 | $1.05 | $1.03 |
09 Dec 2024 | $1.05 | $-0.01 | -0.94% | 2,285,533 | $1.07 | $1.08 | $1.04 |
06 Dec 2024 | $1.07 | $-0.03 | -2.74% | 3,294,561 | $1.09 | $1.11 | $1.07 |
05 Dec 2024 | $1.10 | $-0.02 | -1.80% | 2,028,843 | $1.11 | $1.13 | $1.09 |
04 Dec 2024 | $1.11 | $0.00 | 0.00% | 1,163,079 | $1.12 | $1.12 | $1.10 |
03 Dec 2024 | $1.12 | $-0.01 | -0.88% | 948,971 | $1.13 | $1.14 | $1.11 |
02 Dec 2024 | $1.13 | $-0.01 | -0.88% | 750,353 | $1.14 | $1.15 | $1.13 |
29 Nov 2024 | $1.14 | $-0.01 | -0.87% | 882,768 | $1.15 | $1.16 | $1.14 |
28 Nov 2024 | $1.15 | $-0.01 | -0.87% | 1,085,413 | $1.16 | $1.16 | $1.15 |
27 Nov 2024 | $1.16 | $0.02 | 1.76% | 1,847,022 | $1.13 | $1.16 | $1.13 |
26 Nov 2024 | $1.14 | $0.00 | 0.00% | 1,050,137 | $1.14 | $1.15 | $1.13 |
25 Nov 2024 | $1.14 | $0.03 | 2.73% | 2,732,184 | $1.12 | $1.16 | $1.12 |
22 Nov 2024 | $1.10 | $0.01 | 0.91% | 1,272,130 | $1.11 | $1.11 | $1.09 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
02 Sep 2024 | Natalie Meyenn | Buy | 15,310 | $18,678 |
As advised by the company. Tranche 2 of 2 of the acquisition of units
pursuant to participation in the FY24 voluntary non-executive director unit acquisition |
02 Sep 2024 | Kelly O'Dwyer | Buy | 12,824 | $15,645 |
As advised by the company. Tranche 2 of 2 of the acquisition of units
pursuant to participation in the FY24 voluntary non-executive director unit acquisition |
02 Sep 2024 | Joseph Carrozzi | Buy | 12,513 | $15,265 |
As advised by the company. Tranche 2 of 2 of the acquisition of units
pursuant to participation in the FY24 voluntary non-executive director unit acquisition |
16 May 2024 | Christopher Roberts | Sell | 9,636 | $11,322 |
On-market trade.
|
16 May 2024 | Christopher Roberts | Buy | 85,490 | $100,878 |
On-market trade.
|
18 Mar 2024 | David Di Pilla | Sell | 37,990 | $100 |
As advised by the company. Disposal of further units by Home Consortium
Developments Pty Ltd ACN 635 859 700 for nominal consideration of AUD$100 pursuant to a selective buyback which was approved by HCW unitholders at an EGM on 24 July 2023. |
27 Feb 2024 | Natalie Meyenn | Buy | 13,998 | $18,617 |
As advised by the company. Tranche 1 of 2 of the acquisition of units
pursuant to participation in the FY24 voluntary non-executive director unit acquisition arrangement as summarised in HCW's Product Disclosure Statement dated 2 August 2021. |
27 Feb 2024 | Joseph Carrozzi | Buy | 10,807 | $14,373 |
As advised by the company. Tranche 1 of 2 of the acquisition of units
pursuant to participation in the FY24 voluntary non-executive director unit acquisition arrangement as summarised in HCW's Product Disclosure Statement dated 2 August 2021. |
27 Feb 2024 | Kelly O'Dwyer | Buy | 11,705 | $15,567 |
As advised by the company. Tranche 1 of 2 of the acquisition of units
pursuant to participation in the FY24 voluntary non-executive director unit acquisition arrangement as summarised in HCW's Product Disclosure Statement dated 2 August 2021. |
16 Feb 2024 | David Di Pilla | Buy | 31,912,867 | $42,603,677 |
On-market trade.
|
21 Dec 2023 | David Di Pilla | Sell | 179,175 | $100 |
As advised by the company. Disposal of further units by Home Consortium
Developments Pty Ltd (ACN 635 859 700) for nominal consideration of AUD$100 pursuant to a selective buyback. |
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Dr Christopher Graham Roberts | Non-Executive Director | Aug 2021 |
Dr Roberts has over 40 years of experience in the medical device industry serving a number of senior management positions. He was the former CEO of Cochlear from 2004 to 2015 and is presently a member of the Cochlear Foundation Board and a Non-Executive Director of Sigma Healthcare Limited, Clarity Pharmaceuticals Limited, HMC Capital Partners Fund 1, Atmo Biosciences Ltd, Centenary Institute of Medical Research and Nutromics Pty Ltd. He was also the Executive Vice President of ResMed from 1992 to 2003, and a director until 2017. Chris was a former Chair of Research Australia from 2004 to 2010.
|
Ms Stephanie Mei-Nga Lai | Non-Executive Director | Aug 2021 |
Ms Lai e has over 25 years of experience, is a Chartered Accountant and is a former Transaction Services partner of Deloitte and KPMG. She has experience providing due diligence and advisory services, including forecast reviews to listed entities, sovereign wealth funds, wealth managers and private equity. She is Chair of Risk Committee.
|
Mr David Anthony Di Pilla | Non-Executive Director | Jul 2021 |
Mr Pilla has over 30 years of experience in investment banking, strategic advisory and consulting, and corporate leadership as a Director and CEO. During his 20 years of investment banking career, David was Managing Director of UBS Investment Bank for over 15 years and during this time led some of Australia's landmark transactions across corporate M&A, Equity & Debt Capital Markets. Prior to his time at UBS, David reached the position of Vice President, Investment Banking at JP Morgan.
|
Hon Kelly Megan O'Dwyer | Non-Executive Director | Aug 2021 |
Ms O'Dwyer previously served in the Australian Parliament as a Senior Cabinet Minister holding a number of key economic portfolios including Minister for Jobs and Industrial Relations, Minister for Revenue and Financial Services, Minister for Small Business, and Assistant Treasurer. She also served on the Cabinet's Budget Committee (the Expenditure Review Committee) and held the portfolios of Minister for Women, as well as Minister Assisting the Prime Minister with the Public Service. Prior to entering Parliament, Kelly worked in law, government and finance and brings insights across a range of sectors including funds management, superannuation, workplace relations, foreign investment, law and banking.
|
Mr Joseph Carrozzi | Non-Executive ChairmanNon-Executive Director | Aug 2021 |
Mr Carrozzi has over 25 years of experience as a managing partner in the Big 4 professional services firms. He has experience in infrastructure, health and medical research as well as sectors which are highly regulated. He is currently the Chair of the Centenary Institute for Medical Research, the Angus Knight Group, as well as a board member of the National Intermodal Corporation, the NSW Business Chamber, Football Australia, Aurrum Pty Ltd and ServiceGen Pty Ltd. Joseph was formerly Chair of the Sydney Harbour Federation Trust and Deputy Chair of the NSW Institute of Sport. He is also a member of Risk Committee.
|
Ms Natalie Jane Meyenn | Non-Executive Director | Aug 2021 |
Ms Meyenn has over 25 years of experience in financial services and investing globally. She was Head and Chair of the Investment Committee for MLC Private Equity and is currently co-founder of an agriculture investment firm and adviser and/or investment committee member to a small number of asset management, private equity and non-profits including New Energy Nexus and Yielco Investments. She worked in investment banking (M&A, capital markets and public finance) for Goldman Sachs and Bear Stearns in New York and Sydney and for the World Bank on micro-credit, project finance and climate impact mitigation in Asia, Africa and the Pacific Islands. She is also a member of Risk Committee.
|
Mr Andrew Selim | Company SecretaryGeneral Counsel |
-
|
|
Andrew Selim | Company SecretaryGeneral Counsel |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Home Consortium Developments Limited | 89,871,409 | 16.02% |
J P Morgan Nominees Australia Pty Limited | 80,211,627 | 14.30% |
HSBC Custody Nominees (Australia) Limited | 76,429,553 | 13.62% |
Citicorp Nominees Pty Limited | 36,237,475 | 6.46% |
Home Consortium Limited | 35,034,393 | 6.24% |
BNP Paribas Noms Pty Ltd | 29,916,793 | 5.33% |
Netwealth Investments Limited (Wrap Services A/C) | 7,033,080 | 1.25% |
National Nominees Limited | 5,140,105 | 0.92% |
BNP Paribas Nominees Pty Ltd (HUB24 Custodial Serv Ltd) | 4,858,930 | 0.87% |
BNP Paribas Nominees Pty Ltd (Agency Lending A/C) | 4,444,729 | 0.79% |
HSBC Custody Nominees (Australia) Limited A/C 2 | 3,273,968 | 0.58% |
HSBC Custody Nominees (Australia) Limited (NT COMNWLTH Super Corp A/C) | 2,540,200 | 0.45% |
Netwealth Investments Limited (Super Services A/C) | 2,284,185 | 0.41% |
BNP Paribas Nominees Pty Ltd (Pitcher Partners) | 2,282,189 | 0.41% |
Goat Properties Pty Ltd | 1,986,390 | 0.35% |
Citicorp Nominees Pty Limited (Colonial First State Inv A/C) | 1,609,218 | 0.29% |
Sword Excalibur Equities Pty Ltd (Sword Excalibur EQ 2 A/C) | 1,597,222 | 0.28% |
Glengallan Investments Pty Ltd | 1,188,249 | 0.21% |
Premium Capital (Aust) Pty Ltd | 1,082,000 | 0.19% |
Seymour Group Pty Ltd | 1,078,000 | 0.19% |